儿科用药专栏
LIN Feijin;GAO Yan;CHEN Shumei;ZHAO Jizong;HUANG Jincheng;CUI Minxian
2006, 25(5): 0-0.
ObjectiveTo detect the effect of astragalus for injection together with glucocorticoid on serum levels of IL-10 in children with idiopathic nephrotic syndrome(INS), to analyse their role in INS and the mechanism of astragalus' treatment for INS. MethodsSixtythree children with idiopathic nephrotic syndrome were divided into astragalus group including thirtythree cases and nonastragalus group including thirty cases. In astragalus group, patients were given prednisone 1.5－2.0 mg·kg-1·d-1，P.O., qd, astragalus for injection 0.5 mL·kg-1·d-1, and other symptomatic treatments. In nonastragalus group except astragalus for injection, other treatments were the same as the first group. The serum IL10 levels in all patients between initial stage and one month after therapy were detected. Other 25 healthy children were collected in control group. Serum IL10 levels were detected by a double antibody "sandwich" ELISA. ResultsIn initial stage, there was no significant difference in serum IL10 level between nonastragalus group and astragalus group (14.05±5.57) pg·mL-1 vs (13.39±6.14) pg·mL-1(t＝0.61，P＞0.05), and both were higher than control group ［(14.05±5.57) pg·mL-1 vs (9.48±4.01) pg·mL-1, t＝3.36, P＜0.01, and (13.39±6.14) pg·mL-1 vs (9.48±4.01) pg·mL-1, t＝2.77, P＜0.01］. Serum IL-10 levels in nonastragalus group after prednisone therapy were significantly lower than those before prednisone therapy (9.36±3.43) pg·mL-1 vs (14.05±5.57) pg·mL-1, t＝3.55, P＜0.01, and no significant difference was observed as compared with control group. Compared with those before treatment, Serum IL-10 levels in astragalus group were not significant different in initial stage and one month after prednisone together with astragalus therapy(t＝0.95，P＞0.05. Serum IL10 levels of astragalus group in one month after prednisone together with astragalus therapy were still significantly higher than those in control group(12.10±4.14) pg·mL-1 vs (9.48±4.01) pg·mL-1, t＝2.25,P＜0.05 and nonastragalus group in one month after prednisone therapy(12.10±4.14) pg·mL-1 vs (9.36±3.43)pg·mL-1, t＝2.40,P＜0.05).ConclusionAstragalus for injection can prevent the lowering of serum IL-10 levels in children with idiopathic nephrotic syndrome and counteract the inhibitory effect of hormone on the production of IL-10. This may be one of the mechanism of astragalus for injection to lower the urine protein content in children with INS.
